XML 38 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Discontinued Operations (Tables)
 6 Months Ended
Jun. 30, 2012
Balance Sheet [Member] | Regenerative Medicine - China segment [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The summary of the assets and liabilities related to Regenerative Medicine-China discontinued operations as of December 31, 2011 was as follows (in thousands):
 
December 31, 2011
Assets:
 

Cash and cash equivalents
$
103.3

Prepaid expenses and other current assets
284.4

Property, plant and equipment, net
1,256.8

Other Assets
149.0

 
$
1,793.5

Liabilities:
 
Accounts payable
$
177.8

Accrued liabilities
31.0

 
$
208.8


As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):

Cash
$
195.1

Prepaid expenses and other current assets
14.9

Property, plant and equipment, net
1,023.7

Other Assets
330.5

Accounts payable
(177.1
)
Accrued liabilities
(79.2
)
Accumulated comprehensive income
(169.9
)
Loss on exit of segment
$
1,138.0
Balance Sheet [Member] | Pharmaceutical Manufacturing - China business [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The summary of the assets and liabilities related to Pharmaceutical Manufacturing- China discontinued operations as of June 30, 2012 and December 31, 2011, respectively, were as follows (in thousands):
 
June 30, 2012
 
December 31, 2011
Cash and cash equivalents
$
16,149.2

 
$
8,707.0

Restricted cash
1,115.3

 
—

Accounts receivable, net
7,317.0

 
5,525.7

Inventory
20,445.2

 
16,505.7

Deferred income taxes
350.7

 
463.7

Prepaid expenses and other current assets
1,461.4

 
777.5

Property, plant and equipment, net
36,097.2

 
36,490.4

Land use rights, net
4,856.2

 
4,872.4

Goodwill
—

 
8,495.7

Intangible assets, net
1,352.4

 
21,846.4

Other assets
2,757.8

 
2,459.9

Total assets
$
91,902.4

 
$
106,144.4

 
 
 
 
Accounts payable
$
17,310.5

 
$
7,950.3

Accrued liabilities
1,887.7

 
1,705.8

Bank loans
14,238.0

 
15,712.0

Notes payable
2,230.6

 
—

Income tax payable
1,381.5

 
621.6

Deferred income taxes
5,913.7

 
6,177.4

Unearned revenue
1,216.9

 
1,315.4

Amount due related parties
21,254.9

 
20,862.7

Total Liabilities
$
65,433.8

 
$
54,345.2
Income Statement [Member] | Regenerative Medicine - China segment [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2012
 
2011
 
2012
 
2011
Revenue
$
—

 
$
98.8

 
$
52.3

 
$
148.9

Cost of revenues
—

 
(31.3
)
 
(30.6
)
 
(49.4
)
Research and development
—

 
93.6

 
(103.3
)
 
(64.5
)
Selling, general, and administrative
—

 
(782.3
)
 
(497.3
)
 
(1,572.3
)
Other income (expense)
—

 
1.4

 
(6.8
)
 
(11.3
)
Loss on exit of segment
—

 
—

 
(1,138.0
)
 
—

Loss from discontinued operations
$
—

 
$
(619.8
)
 
$
(1,723.7
)
 
$
(1,548.6
)
Income Statement [Member] | Pharmaceutical Manufacturing - China business [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2012
 
2011
 
2012
 
2011
Revenue
$
18,934.3

 
$
16,151.2

 
$
37,218.3

 
$
34,293.0

Cost of revenues
(12,214.2
)
 
(11,695.7
)
 
(25,580.0
)
 
(24,302.1
)
Research and development
(852.3
)
 
(872.7
)
 
(1,619.7
)
 
(1,102.8
)
Selling, general, and administrative
(3,160.1
)
 
(2,940.2
)
 
(6,200.1
)
 
(6,125.9
)
Other income (expense)
(514.8
)
 
(260.5
)
 
(1,007.4
)
 
(366.1
)
Provision for income taxes
(383.2
)
 
(213.8
)
 
(505.5
)
 
(881.5
)
Asset impairments
(27,994.6
)
 
—

 
(27,994.6
)
 
—

(Loss) income from discontinued operations
$
(26,184.9
)
 
$
168.3

 
$
(25,689.0
)
 
$
1,514.6